当前位置: 首页 >> 检索结果
8021. WHO Collaborating Centre consensus meeting on anti-cytokine therapy in rheumatoid arthritis.
作者: P Emery.;J Y Reginster.;T Appelboom.;F C Breedveld.;E Edelmann.;J Kekow.;M Malaise.;E M Mola.;C Montecucco.;M Sanda.;J Sany.;D L Scott.;U Serni.;G Seydoux.
来源: Rheumatology (Oxford). 2001年40卷6期699-702页
Severe adult rheumatoid arthritis is a cause of progressive disability and increased mortality across Europe. A cure for the disease remains elusive, but control of symptoms and maintenance of individual independence is possible. Anti-cytokine therapies offer a new approach to disease management. They are effective after the failure of full doses of methotrexate, and are at least as effective as methotrexate in retarding the progression of radiological changes. Until more is known about the long-term safety and efficacy of these drugs they should be reserved for patients with severe disease who are progressing despite adequate doses of methotrexate or other disease-modifying anti-rheumatic drugs. They should be continued until therapeutic failure or intolerance. A comprehensive health economic evaluation is needed to optimally direct the use of these drugs. This should be undertaken when long-term safety and efficacy studies are completed.
8022. Prediction of depression in systemic lupus erythematosus patients using SF-36 Mental Health scores.
作者: T Stoll.;Y Kauer.;S Büchi.;R Klaghofer.;T Sensky.;P M Villiger.
来源: Rheumatology (Oxford). 2001年40卷6期695-8页
As depression is common in systemic lupus erythematosus (SLE) patients, we investigated whether and how the Medical Outcome Survey Short Form 36 (SF-36) scores, routinely used in the assessment of SLE patients, would indicate the absence or presence of depression.
8023. Radiographic signs of bone destruction in the arthritic temporomandibular joint with special reference to markers of disease activity. A longitudinal study.
To investigate the progression of radiographic changes of the temporomandibular joint (TMJ) with reference to plasma levels of interleukin-1beta (IL-1beta), C-reactive protein (CRP) and disease duration.
8024. Hyperhomocysteinaemia in Behçet's disease.
作者: K Aksu.;N Turgan.;F Oksel.;G Keser.;D Ozmen.;G Kitapçioğlu.;G Gümüşdiş.;O Bayindir.;E Doğanavşargil.
来源: Rheumatology (Oxford). 2001年40卷6期687-90页
Arterial and venous thrombosis are among the clinical features of Behçet's disease (BD), the pathogenesis of which is not completely understood. In this study, we investigated whether hyperhomocysteinaemia, being a well known risk factor for thrombosis, is also a contributive risk factor for the arterial and venous thrombosis of BD.
8025. Antibodies to Th/To ribonucleoprotein in patients with localized scleroderma.
作者: K Yamane.;H Ihn.;M Kubo.;M Kuwana.;Y Asano.;N Yazawa.;K Tamaki.
来源: Rheumatology (Oxford). 2001年40卷6期683-6页
Antibodies to Th/To ribonucleoprotein (anti-Th/To) have been detected almost exclusively in patients with systemic sclerosis. Therefore, we aimed to determine the prevalence of anti-Th/To in patients with localized scleroderma.
8026. Osteoclast-like cells in an in vitro model of bone destruction by rheumatoid synovium.
作者: Y Suzuki.;Y Tsutsumi.;M Nakagawa.;H Suzuki.;K Matsushita.;M Beppu.;H Aoki.;Y Ichikawa.;Y Mizushima.
来源: Rheumatology (Oxford). 2001年40卷6期673-82页
Osteoclasts may be involved in the process of rheumatoid bone destruction. To test this hypothesis, we developed an in vitro model of bone destruction by osteoclast-like cells derived from cultured rheumatoid synovial tissue without using any inducers.
8027. Lack of association of HLA-B*51 with a severe disease course in Behçet's disease.
作者: A Gül.;F A Uyar.;M Inanc.;L Ocal.;I Tugal-Tutkun.;O Aral.;M Koniçe.;G Saruhan-Direskeneli.
来源: Rheumatology (Oxford). 2001年40卷6期668-72页
To investigate the previously reported association of HLA-B51 with the manifestations and severity of Behçet's disease (BD).
8028. Association of CTLA-4 but not CD28 gene polymorphisms with systemic lupus erythematosus in the Japanese population.
作者: S Ahmed.;K Ihara.;S Kanemitsu.;H Nakashima.;T Otsuka.;K Tsuzaka.;T Takeuchi.;T Hara.
来源: Rheumatology (Oxford). 2001年40卷6期662-7页
Systemic lupus erythematosus (SLE) in a multisystem autoimmune disorder characterized by multiorgan pathology and autoantibodies against a variety of autoantigens. The CD28 and CTLA-4 genes might be candidate genes for SLE, because costimulation signals from CD80/CD86 to CD28/CTLA-4 have been suggested to play an important role in the activation or inactivation of T lymphocytes.
8029. Elevated interleukin-6 plasma levels are regulated by the promoter region polymorphism of the IL6 gene in primary Sjögren's syndrome and correlate with the clinical manifestations of the disease.
作者: J Hulkkonen.;M Pertovaara.;J Antonen.;A Pasternack.;M Hurme.
来源: Rheumatology (Oxford). 2001年40卷6期656-61页
To determine whether plasma interleukin-6 (IL-6) and G/C base exchange polymorphism at position -174 of the IL6 gene have an effect on the clinical manifestations of primary Sjögren's syndrome (pSS).
8030. Thrombosis in Behçet's disease: a retrospective survey from a single UK centre.
To contribute to knowledge of vascular occlusion in Behçet's disease (BD), prevalence and relative risk for thrombosis were ascertained retrospectively in a cohort of Caucasian patients with the disease.
8031. Provision of Internet-based rheumatology education (http://rheuma.bham.ac.uk).
作者: A S Wilson.;G D Kitas.;P Llewellyn.;D M Carruthers.;D C Cheseldine.;S Harris.;A P Huissoon.;P A Bacon.;S P Young.
来源: Rheumatology (Oxford). 2001年40卷6期645-51页
The Internet is becoming an important way of delivering medical information, and if used appropriately may assist in improving patients' self-management of their disease. We have established an arthritis education website ('Arthritis Help') and investigated its use over the last 2 yr.
8032. Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis.
作者: A McEntegart.;H A Capell.;D Creran.;A Rumley.;M Woodward.;G D Lowe.
来源: Rheumatology (Oxford). 2001年40卷6期640-4页
To compare prevalent cardiovascular disease, conventional cardiovascular risk factors and thrombotic variables in a cohort with well-controlled rheumatoid arthritis (RA) and in population controls.
8033. Patient-relevant outcomes fourteen years after meniscectomy: influence of type of meniscal tear and size of resection.
To study long-term patient-relevant outcomes after meniscectomy, a surgical procedure associated with a high risk of knee osteoarthritis (OA). Principal objectives were to compare traumatic with degenerative meniscal tear and partial with subtotal meniscectomy.
8034. Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint.
作者: D R Haynes.;T N Crotti.;M Loric.;G I Bain.;G J Atkins.;D M Findlay.
来源: Rheumatology (Oxford). 2001年40卷6期623-30页
This study investigated the involvement of the recently identified regulators of osteoclast formation RANKL [receptor activator of nuclear factor kappaB (RANK) ligand, osteoclast differentiation factor, TRANCE, osteoprotegerin ligand] and its natural inhibitor, osteoprotegerin (OPG), in the bone erosion of rheumatoid arthritis (RA).
8035. Effects of the American College of Rheumatology systemic sclerosis trial guidelines on the nature of systemic sclerosis patients entering a clinical trial.
作者: D E Furst.;P J Clements.;W K Wong.;M D Mayes.;F Wigley.;B White.;M Weisman.;W Barr.;L Moreland.;R Martin.;T A Medsger.;V Steen.;D Collier.;A Weinstein.;E Lally.;J Varga.;S R Weiner.;B Andrews.;M Abeles.;J B Peter.;J R Seibold.
来源: Rheumatology (Oxford). 2001年40卷6期615-22页
To compare the systemic sclerosis (SSc) patients entered into the d-penicillamine trial with SSc patients entered into previous controlled SSc trials. It was hypothesized that the d-penicillamine trial patients, who conformed to the American College of Rheumatology (ACR) guidelines for clinical trials in SSc were different from patients entered into previous trials.
|